Category and working mechanisms of SARS-CoV-2 vaccines and their effectiveness in clinical trials
10.19428/j.cnki.sjpm.2021.20991
- VernacularTitle:新型冠状病毒疫苗的种类、机制及临床试验效果
- Author:
Jian-sheng LIN
1
;
Jia-ying SHEN
2
;
Guang-wen CAO
3
Author Information
1. School of Medicine， Jinan University， Guangzhou， Guangdong 510632， China
2. Tongji University School of Medicine， Shanghai 200331， China
3. Department of Epidemiology， Naval Medical University， Shanghai 200433， China
- Publication Type:Research Article
- Keywords:
COVID-19;
vaccine;
vaccine category;
clinical trial
- From:
Shanghai Journal of Preventive Medicine
2021;33(11):1088-1095
- CountryChina
- Language:Chinese
-
Abstract:
Since the pandemic outbreak of the COVID-19， there had been about 121 million confirmed cases and more than 2.6 million deaths， which had significantly affected the economies and health resources in more than 233 countries and regions. Currently， no effective therapeutic option is available for the COVID-19， andimplementation of public health interventions suffers inconvenience. Consequently， the development of COVID-19 vaccines remains crucial. This review updates the current research progression， advantages and disadvantages of inactivated vaccine， live attenuated vaccine， recombinant subunit vaccine， recombinant virus-vectored vaccine， DNA vaccine， and RNA vaccine for the COVID-19. It warrants joint research and development of vaccines on multiple platforms， which would facilitate better control and prevention of the COVID-19 epidemic.
